Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Semaglutide for the Silent Phenotype: A Translational Signal in Obesity-Driven HFpEF.

The American journal of cardiology - 1 Sept 2026

Ceravolo Roberto, Lucà Fabiana, Gulizia Michele M, Nardi Federico, Grimaldi Massimo, Gelsomino Sandro

Abstract excerpt

Obesity-related heart failure with preserved ejection fraction (HFpEF) represents an increasingly prevalent clinical phenotype characterized by exercise intolerance, systemic inflammation, and limited therapeutic options. Semaglutide, a glucagon-like peptide-1 receptor agonist approved for obesity management, has shown favorable effects on symptoms and cardiometabolic markers in patients with HFpEF and obesity,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Heart Failure
Share to Natriuretic Peptide, Brain

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Obesity

Share to Phenotype

Share to Stroke Volume

Source

Identifiers

PMID: 42342009
DOI: 10.1016/j.amjcard.2026.06.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Semaglutide for the Silent Phenotype: A Translational Signal in Obesity-Driven HFpEF.PMID 42342009Read ↗

Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.Semantic proximity Read ↗

Defining the Phenotypes for Heart Failure With Preserved Ejection Fraction.Semantic proximity Read ↗

One small STEP, one giant leap: Semaglutide in the obese phenotype of heart failure with preserved ejection fraction.Semantic proximity Read ↗

Targeting Metabolic Dysfunction and Inflammation with Sotagliflozin Reverses Diastolic Dysfunction in Experimental HFpEFSemantic proximity Read ↗

Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.Semantic proximity Read ↗

Obesity/cardiometabolic phenotype of heart failure with preserved ejection fraction: mechanisms to recent trials.Semantic proximity Read ↗

Cardiometabolic heart failure with preserved ejection fraction: from molecular signatures to personalized treatment.Semantic proximity Read ↗

Salt-inducible kinase inhibition promotes weight loss and improves the diastolic function of obesity-related heart failure with preserved ejection fraction in miceSemantic proximity Read ↗

Combined Semaglutide and Exercise Ameliorate HFpEF-Associated MASH: Multi-Omics InsightsSemantic proximity Read ↗

Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.Semantic proximity Read ↗

Does Characterization of Phenotypic Heterogeneity Provide Mechanistic Insights or Influence the Response to Treatment? Experience in Positive and Neutral Trials in Patients With Heart Failure and a Preserved Ejection Fraction.Semantic proximity Read ↗

Pathophysiological understanding of HFpEF: microRNAs as part of the puzzle.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.